Semaglutide
-
Post Date:
Sep 15,2025
-
Expiry Date:
Mar 14,2026
-
Detailed Description:
Cas No. :910463-68-2
Specs:99%up,DMF
Semeglutide is a long-acting glucagon-like peptide 1 (GLP-1) analog, a GLP-1 receptor agonist, and has potential therapeutic efficacy in type II diabetes mellitus (T2DM).
Compared with liraglutide, semaglutide has a longer aliphatic chain and increased hydrophobicity, but semaglutide is modified with a short chain of PEG, and its hydrophilicity is greatly enhanced. After PEG modification, it can not only bind closely to albumin, cover the enzymatic hydrolysis site of DPP-4, but also reduce renal excretion, prolong the biological half-life, and achieve the effect of long circulation.
*Products under the patent are only for R&D use.
-
CAS Registry Number:
910463-68-2
-
Synonyms:
;Sermaglutide;
-
Molecular Structure:
Inquiry